PCSK9 and coronary atherosclerosis progression beyond LDL‐cholesterol in coronary artery disease patients
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.70083 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Rosetta Ragusa und 7 weiteren Autor:innen. Beteiligte Einrichtung: CNR, Institute of Clinical Physiology, Pisa, Italy. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Coronary Artery Disease, Cholesterol, LDL, Plaque, Atherosclerotic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union H2020-PHC-2015-single-stage, Amgen, NextGenerationEU-NRRP M6C2-Investment 2.1 Enhancement and strengthening of biomedical research in the NHS.
Abstract (Originalsprache)
Background
This study evaluated whether plasma PCSK9 is associated with coronary plaque progression in patients with coronary artery disease (CAD) and assessed its involvement in molecular processes of atherogenesis.
Methods
Plasma PCSK9 was measured in 159 patients with stable CAD submitted to coronary computed tomography angiography (CTA) at baseline and after a follow‐up of 6.5 ± 1.1 years. Plaque progression was defined as the annual increase in Total, Fibrous, Fibro‐fatty, Necrotic‐Core and Dense‐Calcium plaque volumes (PV). Pathways linked with PCSK9 were studied by RNA‐sequencing of whole blood and in vitro studies using endothelial cells (EC).
Results
At multivariable analysis, plasma PCSK9 was associated with an annual increase in Necrotic‐Core PV ( p = .022) independent of cardiovascular risk factors, molecular markers, and medications, including LDL‐C and statins. At RNA‐seq analysis, PCSK9 was linked to the expression of genes involved in the innate‐immune response. Treating EC with PCSK9 resulted in a significant increase in ICAM‐1, VCAM‐1, MCP1 and IL6 mRNA expression.
Conclusions
In patients with CAD, plasma PCSK9 is associated with progression of Necrotic Core‐PV. The link with inflammatory pathways suggested for PCSK9 a potential role for the occurrence of prognostically adverse plaque phenotypes beyond LDL‐C regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CNR, Institute of Clinical Physiology, Pisa, Italy.
- Department of Cardiology, Heart Lung Center, Leiden University Medical Centre, Leiden, The Netherlands.
- Fondazione Toscana G. Monasterio, Pisa, Italy.
ORCID-Profile: Chiara Caselli
Förderung
- European Union H2020-PHC-2015-single-stage
- Amgen
- NextGenerationEU-NRRP M6C2-Investment 2.1 Enhancement and strengthening of biomedical research in the NHS
Zitieren
APA
Ragusa, R., Rocchiccioli, S., Del Turco, S., Morlando, A., Basta, G., Scholte, A., Neglia, D., & Caselli, C. (2025). PCSK9 and coronary atherosclerosis progression beyond LDL‐cholesterol in coronary artery disease patients. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70083
Vancouver
Ragusa R, Rocchiccioli S, Del Turco S, Morlando A, Basta G, Scholte A, et al. PCSK9 and coronary atherosclerosis progression beyond LDL‐cholesterol in coronary artery disease patients. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70083
BibTeX
@article{Ragusa2025,
author = {Ragusa, Rosetta and Rocchiccioli, Silvia and Del Turco, Serena and Morlando, Antonio and Basta, Giuseppina and Scholte, Arthur and Neglia, Danilo and Caselli, Chiara},
title = {PCSK9 and coronary atherosclerosis progression beyond LDL‐cholesterol in coronary artery disease patients},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.70083}
}
EUVIMED